Abstract
The aim of this study was to investigate the possible inhibitory effect of ipriflavone on bone resorption in rats. For this purpose, 10-week-old, intact and ovariectomized (OVX) rats, prelabeled from birth with [3H]tetracycline, were used. Bone resorption was monitored by measuring the urinary excretion of [3H]. The animals were fed a purified diet devoid of naturally occurring flavonoids. In the intact rats, the daily meal was given either as a single portion or divided into four portions, a procedure known to lead by itself to a decrease in bone resorption. Ipriflavone, given 7 days after OVX at the dose of 400 mg/kg B.W. daily mixed with the food, led within 2–3 days to a significant decrease in bone resorption equivalent to that of 27.2 μg/kg S.C. of 17β-estradiol. The inhibition was sustained for the length of the experiment, up to 21 days. Ipriflavone given 7 days before OVX prevented the increase in bone resorption induced by castration, the effect being dose-dependent between 50 and 400 mg/kg B.W. In contrast to 17β-estradiol, a 5-week treatment with ipriflavone failed to prevent the OVX-induced uterine atrophy. Significant inhibition of bone resorption was also seen in intact animals, provided they rapidly ingested the daily meal. Actually, the decrease in bone resorption induced by portioning the daily food masked the inhibitory effect of ipriflavone in intact animals. In conclusion, ipriflavone can decrease bone resorption in both intact and OVX animals given a purified diet as a single daily meal. In the OVX model, ipriflavone mimics the osteoprotective effect of estrogen. However, the lack of a uterotropic effect suggests that the compound can discriminate between bone and reproductive tissues.
Similar content being viewed by others
References
Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passed M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82–91
Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333–337
Valente M, Bufalino L, Castiglione GN, D’Angelo R, Mancuso A, Galoppi P, Zichella L (1994) Effect of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 54:377–380
Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M (1992) Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 51:S3-S6
Morita I, Sakagushi K, Kurachi T, Murota S (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51:S7-S10
Bonucci E, Ballanti P, Martelli A, Mereto E, Brambilla G, Bianco P, Bufalino L (1992) Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 50:314–319
Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987–996
Notoya K, Yoshida K, Tsukuda R, Taketomi S (1994) Effect of ipriflavone on expression markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture. J Bone Miner Res 9:395–400
Yamazaki I, Shino A, Tsukuda R (1986) Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. J Bone Miner Metab 3:205–210
Mühlbauer RC, Fleisch H (1990) A method for continual monitoring of bone resorption in rats: evidence for a diurnal rhythm. Am J Physiol 259:R679-R689
Mühlbauer RC, Fleisch H (1995) The diurnal rhythm of bone resorption in the rat. Effect of feeding habits and pharmacological inhibitors. J Clin Invest 95:1933–1940
Cassidy A, Bingham S, Setchell KDR (1994) Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60: 333–340
Petilli M, Fiorelli G, Benvenuti S, Frediani F, Gori F, Brandi ML (1995) Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 56:160–165
Yamazaki I (1986) Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci 38:757–764
Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P (1992) Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 15:755–761
Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU (1994) Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63–69
Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD (1995) Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136: 2435–2441
Black LJ, Jones CD, Falcone JF (1983) Antagonism of estrogen action with a new benzothiophene-derived antiestrogen. Life Sci 32:1031–1036
Eppenberger U, Wosikowski K, Kung W (1991) Pharmacologie and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol (suppl 2) 14:S5-S14
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cecchini, M.G., Fleisch, H. & Mühlbauer, R.C. Ipriflavone inhibits bone resorption in intact and ovariectomized rats. Calcif Tissue Int 61 (Suppl 1), S9–S11 (1997). https://doi.org/10.1007/s002239900377
Issue Date:
DOI: https://doi.org/10.1007/s002239900377